MARKET

EXEL

EXEL

Exelixis Inc
NASDAQ
52.99
+1.25
+2.42%
After Hours: 52.99 0 0.00% 16:48 06/09 EDT
OPEN
52.53
PREV CLOSE
51.74
HIGH
53.28
LOW
52.01
VOLUME
1.77M
TURNOVER
--
52 WEEK HIGH
53.28
52 WEEK LOW
33.76
MARKET CAP
13.32B
P/E (TTM)
17.56
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at EXEL last week (0601-0605)?
Weekly Report · 1d ago
How Broad CABOMETYX PFS Benefit At Exelixis (EXEL) Has Changed Its Investment Story
Simply Wall St · 2d ago
CABINET Results Broaden CABOMETYX Neuroendocrine Reach And Investor Considerations
Simply Wall St · 3d ago
Exelixis director Jack L. Wyszomierski sells 3,925 common shares for $198,408.75
PUBT · 5d ago
Exelixis director Sue Gail Eckhardt sells 9,812 shares for $491,974.68
PUBT · 5d ago
Weekly Report: what happened at EXEL last week (0525-0529)?
Weekly Report · 06/01 10:07
Exelixis announces results from subgroup analysis of Phase 3 Cabinet trial
TipRanks · 05/31 13:40
Should New ASCO Colorectal Cancer Data on Zanzalintinib Reshape Exelixis' (EXEL) Investment Narrative?
Simply Wall St · 05/30 14:07
More
About EXEL
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.

Webull offers Exelixis Inc stock information, including NASDAQ: EXEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EXEL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EXEL stock methods without spending real money on the virtual paper trading platform.